Navigation Links
Heart patients are often not treated in accordance with guidelines
Date:11/21/2008

Many patients with cardiovascular disease are not given adequate drug therapy. This is the result of an international study. In the current edition of Deutsches rzteblatt International (Dtsch Arztebl Int 2008; 105[45]: 769-75), Uwe Zeimer et al. present the German results of this prospective, one-year survey.

512 doctors in Germany took part in the study. They enrolled 5594 patients in all, of whom 89.2% suffered from one or more cardiovascular diseases and 10.8% only exhibited risk factors. Documented risk factors included high blood pressure, disturbances in lipid metabolism, diabetes, and obesity. The results showed that several vascular beds were affected simultaneously in almost one third of patients. Many patients also suffered from other diseases requiring treatment, which were defined as risk factors. After one year, 2.1% of the patients with cardiovascular disease and 1.5% of the patients with at least three risk factors had died.

The study demonstrated that only three quarters of patients were given drugs to reduce fat levels. The same proportion was given drugs to dilute blood. Moreover, the doctors failed to exhaust the possibilities for drug treatment. This may be the reason that 27% of the patients with high blood pressure failed to reach the target blood pressure and 66% of the patients with disturbances in lipid metabolism failed to reach the target cholesterol level.


'/>"/>

Contact: Elke Bartholomaeus
bartholomaeus@aerzteblatt.de
49-223-470-11133
Deutsches Aerzteblatt International
Source:Eurekalert

Page: 1

Related medicine news :

1. Drug for cluster headaches may cause heart problems
2. Use of certain lipid measures not more effective in predicting coronary heart disease
3. Restricting Blood Flow May Help Heart Bypass Patients
4. Urban Smog Tough on Young Adults Hearts
5. Stanford study highlights cost-effective method of lowering heart disease risks
6. Vitamin Es lack of heart benefit linked to dosage
7. Drug That Lowers Resting Heart Rate Being Tested
8. Heart Attack Boosts Diabetes Risk
9. Embryonic Stem Cells Repair Human Heart
10. U of M study: Early treatment can reverse heart damage
11. Embryonic Human Stem Cells May Help Repair Heart Muscle, Lab Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, ... ... a non-profit medical society dedicated to advancing the science and clinical practice ... from its RSSearch Patient Registry, a multi-institutional, observational registry established to standardize ...
(Date:3/28/2017)... ... ... Alert Sentry Group LLC., a leader in the Personal Emergency Response System industry, introduced ... Plus. These iSAFE products are the most affordable and most advanced medical alert systems ... direct GPS Location and two-way calling with the push of a button on a ...
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul Thomas; Dr. ... , Medical doctors and PhD scientists will speak to the press on behalf of ... support of an independent vaccine safety commission. , WHERE: , Zenger Room, National ...
(Date:3/28/2017)... , ... March 28, 2017 , ... The Radiology ... FRBMA, has begun to serve as its new executive director. Mr. Still was selected ... Search Committee. , “Bob, as he is known to our members, has been ...
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning medical ... begin serving as new board chair for Orange County health care system CalOptima ... remainder of soon-to-be former chair Mark Refowitz’s term, which runs through June 30 ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 28, 2017  Orexigen Therapeutics, Inc. (Nasdaq: ... the fourth quarter and year ended December 31, 2016. ... transformational progress for Orexigen, beginning with the re-acquisition of ... early March, the team at Orexigen demonstrated remarkable focus, ... reshaped and strengthened our Company while rewarding us full ...
(Date:3/28/2017)... 2017 The global market for ... the top three companies, namely Shimadzu Corporation, Thermo Fisher ... 49% of the overall market in 2015, observes Transparency ... is intensely competitive and has few players, most of ... factors have restricted the entry of new players in ...
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 /PRNewswire/ ... Israel . This new business entity, Emosis Ltd, headquartered ... to research and development of novel assays complementing the mother company ... relevant, locally support commercialization and sales development of Emosis kits. ... This strategic move starts ...
Breaking Medicine Technology: